Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
16 results
D2.332 - First reported case of IgE-mediated food allergy to Tetragonia tetragonioides (New Zealand spinach)
D2.337 - REMA Score Outperforms C-kit and Tryptase in Identifying Mast Cell Disorders in Hymenoptera Venom Allergy
D2.333 - Glatiramer acetate: when immunomodulation is not enough
D2.336 - Risk of systemic reactions among school-age children sensitized to fish, crustaceans and molluscs
D2.338 - Gaps in Adrenaline Autoinjector Education Among Patients at Risk of Anaphylaxis: A Cross-Sectional Study
D2.341 - Comparative Evaluation of Diagnostic Criteria for Food Allergy–Induced Anaphylaxis: Accuracy, Clinical Applicability, and Validation
D2.342 - Environmental Exposure Predicts Severity of Hymenoptera Venom Anaphylaxis Better Than Classical Biomarkers: Added Value of Component-Resolved Diagnostics
D2.343 - Anaphylactic Reaction to Methylprednisolone Acetate in a Young Adult
D2.344 - National Data on Anaphylaxis in Brazil: Findings from the Brazilian Registry
D2.345 - Successful Desensitization in a Pediatric Patient Who Developed an Immediate-Type Systemic Hypersensitivity Reaction to FVIII/vWF Concentrate
D2.346 - When cold triggers anaphylaxis
D3.157 - Clinical characteristics and associated factors of persistent asthma in preschool children with wheezing in a tropical region
D3.165 - Phase 1 study of CDX-622, a bispecific antibody targeting TSLP and mast cells via stem cell factor
D3.155 - Th2–Th17 immune shift following dupilumab therapy
D3.160 - Study of the allergic sensitization profile in asthmatic patients consulting at ignace deen university hospital, conakry
D3.164 - Early and Sustained Effect of Zumilokibart (APG777) in Atopic Dermatitis and Asthma: 16-Week Results from the Phase 2 APEX Study in Moderate-to-Severe AD and a Phase 1b Study in Mild-to-Moderate Asthma
Download the app
The congress at your fingertips
Available on
Download